Home / Transcripts / Lumexa Imaging Holdings, Inc. (LMRI) · November 10, 2026

Lumexa Imaging Holdings, Inc. (LMRI) Earnings Call Transcript

November 10, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 49 min

Earnings Call Speaker Segments

Sue Dooley executive
#1

Thanks, and good morning, everyone. We're glad to have you with us today. Our Chief Executive Officer, Caitlin Zulla, and Tony Martin, our Chief Financial Officer, are leading today's call. Before we get started, I should mention that this discussion will contain forward-looking statements, including statements about our 2026 guidance, expected operating performance, growth initiatives, reimbursement assumptions, capital expenditures, and other future events. Those statements reflect our present expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially. For more information about those risks and uncertainties, please refer to the forward-looking statements and risk factors described in today's earnings release and our most recent SEC filings; we undertake no obligation to update those statements. We will also discuss certain non-GAAP financial measures. Today's earnings release includes definitions and reconciliations to the most directly comparable GAAP measures. With that, I'll now hand the call over to Caitlin. Caitlin, please go ahead.

Caitlin Zulla executive
#2

Thanks, Sue. And before we begin, I'd like to wish everyone a happy Radiologic Technology Week and say a big thank you to this valued part of our community, as well as our entire team at Lumexa. To those of you in our investor audience, thank you for joining us. It's an exciting time to be leading in imaging, and we're eager to take you through our results tonight; during Q3 we moved our strategic priorities forward and got closer to our ambition of building the premier platform for high-quality, lower-cost outpatient imaging, serving patients, physicians, and health systems. We're executing well on every priority, and those efforts flowed directly into favorable results this quarter, including healthy EBITDA, up 11% from Q2, plus yet another quarter of strong free cash flow generation. Here are a few Q3 performance highlights. Our core business continued to show strength. We generated healthy growth in systemwide same-center volumes, kept momentum in advanced modalities across our enterprise, saw continued maturation of our de novo cohorts, and made important headway expanding health system partnerships. Advanced modalities, a key profitability driver for us, rose to a record high 38.2% of total volume systemwide, which is 145 basis points above a year ago. PET stood out as another Q3 highlight, posting 19.5% year-over-year growth. Our shift in advanced modality mix remains a cornerstone of the growth strategy, producing higher reimbursement and margin for the business. Both our 2024 and 2025 de novo cohorts continue tracking in line with what we expected. We just completed another careful review, and they are layering in a healthy mix of advanced volume while making meaningful strides toward our long-term objectives for growth and profit expansion. We hit another significant milestone for our JV strategy, an expanded joint venture with Advocate Health, our existing partner, that takes our enterprise into Illinois, a new state for Lumexa Imaging. We're excited to grow alongside this prestigious health system partner, and we're now fortunate to count 10 health system joint ventures across our enterprise. Our joint venture pipeline is maturing, with discussions moving forward and prospective partners engaging actively around our offering, backed by valuable references from existing JV partners. We look forward to sharing more as those discussions progress. In early November, we're opening three new de novo centers in Texas, South Carolina, and North Carolina; these openings reflect our disciplined approach to expanding in attractive markets, building greater density across our network, and extending our runway for long-term sustainable growth. With these centers, we'll have five de novo openings under our belt for the year, with a clear line of sight into completing our goal of eight to 10 de novo center openings in 2026, and we see an 8% to 10% expansion path taking shape as those centers mature. We're also well underway with our plans for new 2027 center openings. These highlights show progress on our key growth initiatives; they're driving strong, durable cash generation and strengthening our confidence that we'll deliver on our full-year commitments, including the updated guidance we're providing tonight. Tony will cover that in more detail soon. The results we posted for Q3 reflect solid execution, and that strengthens the base we're building for growth over the long term. Just as we've observed in ambulatory surgery, our view is that shifting care into outpatient settings that are high quality and lower cost can widen access and generate meaningful value throughout healthcare. In imaging we see a considerable opportunity in front of us, and Lumexa is positioned well to help lead that transition by expanding our network of wholly owned imaging centers and by partnering with health systems to broaden access, speed up diagnosis, and grow their outpatient footprint, all while delivering better value to patients. I'm proud of how our team is progressing and of the energy they bring to their work at Lumexa each day. I want to spend a moment on the market opportunity we're pursuing. CMS has now finalized its 2027 Hospital Outpatient Prospective Payment System rule on site neutrality. That landmark site-neutral provision will reduce the reimbursement advantage that hospital outpatient departments enjoy and reinforces the case for health systems to add lower-cost, freestanding imaging capacity. Our belief is that the site-neutral rule expands our addressable market in a meaningful way; we now are targeting hospital outpatient imaging centers, a $44 billion incremental opportunity on top of our existing $33 billion market for IDTF, which brings our total addressable market to roughly $77 billion. Imaging, in our view, is a critical front door to diagnosis, treatment, and specialty care. Health systems are increasingly recognizing how important that connection is, and Lumexa is built to help them make it stronger. Our value extends beyond running imaging centers. We help our partners widen access, keep patients connected to their care networks, and improve financial performance. With our model, health systems can scale strategically and participate in outpatient imaging growth through a lower-cost operating structure that doesn't rely on hospital-based reimbursement premiums. We supply the operating expertise, technology, patient access capabilities, and disciplined capital deployment required to grow and build these networks. We see the shift toward site-neutral reimbursement as a tailwind that would unfold over years, not quarters. Durable demand drivers across our imaging network support our broader growth opportunity: an aging population with increasingly complex conditions, new treatments that require advanced imaging, and expanding opportunities for early detection and screening. On top of that, CMS has issued its final 2027 Medicare Physician Fee Schedule. Medicare fee-for-service and Medicare Advantage together represent about 20% of our revenue, a small portion of our overall business. Our analysis is still being completed, but our preliminary assessment is that Medicare reimbursement will land modestly below our longstanding rate assumptions, which call for government reimbursement rates that are approximately flat year-over-year and a 1% increase in commercial payer rates. Commercial payers account for the majority of our revenue, and those contracts renew on staggered schedules. Because almost every one of our 2027 commercial negotiations is now complete, we have solid visibility into next year's rates. Taking everything together, we expect the final rule will have only a modest impact on our overall 2027 reimbursement outlook, with an anticipated range of 8% to 10%. What we offer really resonates with patients, providers, health systems, and payers. Whether through centers we own entirely or those run as JVs, we're delivering high-quality imaging in places that are more convenient, faster to access, and cheaper than hospital outpatient departments. Across our whole network of centers, patients are extremely happy with the care they receive, and you can see that in net promoter scores that keep landing above 90. The market in front of us is huge and full of promise. Our growth priorities are straightforward: push same-center growth, broaden our advanced imaging mix, open new centers and ramp them up, scale strategic service lines, and get into attractive markets via disciplined partnerships that are capital-efficient. Volume, rate, and mix are the bedrock of this strategy. Since our existing centers already cover substantial fixed costs, extra volume, better reimbursement, and modality mix can deliver attractive incremental margins; with this operating leverage, earnings can grow more quickly than revenue as we steer more patients through our established network. Let me share how we're putting these priorities to work. Our operations and commercial teams are partnering with clinical leaders to roll out impactful programs that improve care and drive engagement across our entire network of centers, and in doing so we expect to capture an 8% to 10% improvement.

Caitlin Zulla executive
#3

Particularly through the usual seasonal pattern tied to deductible resets, we are leaning in so we can optimize for patients and serve them. For Breast Cancer Awareness Month, we teamed up with Levine Cancer Institute and the Atrium Health Foundation on Project PINK, offering free screening mammograms plus follow-up care to uninsured and underinsured women across the Charlotte area, which brings early detection to patients and communities where the need is greatest. We are continuing our lung cancer screening initiative, building patient engagement around one of the most impactful screening opportunities within our patient population. Targeted clinical outreach efforts such as these remain a strength for our company. Let me spend a moment on technology, which is a major force behind clinical and operational excellence at Lumexa and sets us apart as we work with leading health systems and physician groups. To begin, I'm delighted to announce that Dr. Aice Piros is coming to Lumexa as our new Chief Clinical AI Officer — a distinguished diagnostic radiologist and clinical information specialist known broadly for his groundbreaking research where medical imaging and AI meet; in this new position, Dr. Piros is going to work alongside our Chief Technology Officer and our Chief Medical Officer. Their focus will be on reshaping how radiologists work and on better outcomes for patients — linking clinical practice with cutting-edge technology to drive our AI strategy, streamlining clinician workflows, and delivering faster, more accurate results for patients. We're also moving Lumexa Connect forward, our capital-light, best-of-breed technology platform built on an ecosystem of leading technologies. That approach lets us adopt innovation quickly as the landscape changes, while supporting new centers, growing joint venture partnerships, and increasing volumes across advanced imaging modalities. Lumexa Connect is already producing results. FastScan, now deployed across the majority of our enterprise, cuts MRI acquisition times by as much as 40% and adds capacity across our fleet. Virtual MRI delivers support for technologists, flexibility in staffing, and consistency in operations. Every one of our telerad radiologists—100%—now relies on AI-enabled reporting tools. We keep bringing in best-in-class draft reporting and EMR summarization tools, which boost radiologist efficiency and ease the administrative load at the point of care. Here at Lumexa, we're digitizing the radiology workflow from start to finish so our network gains greater quality, efficiency, and consistency, while we remain positioned to seize the next generation of AI-enabled innovation. In closing, our Q3 progress strengthens our confidence in the strategy and in our capacity to meet our full-year commitments; we're intent on finishing 2026 strong while laying the groundwork for sustained growth. Our new centers are ramping. Advanced imaging makes up a larger portion of what we offer. We have a strong set of joint venture opportunities in the works, and we're moving into additional markets alongside outstanding health system partners. Taken together, these steps put us in position to broaden access to care and provide a compassionate patient experience, while also building long-term value for our shareholders. With that, I'll hand the call to Tony, who will walk through our financials, key metrics, and guidance. Tony, please go ahead.

Tony Martin executive
#4

Thanks, Caitlin, and thanks to everyone for being with us. This evening I'll walk through our financial results and talk about the main drivers behind how we performed this quarter. After that, I'll share our outlook for the full year. To give you more context than the GAAP figures alone provide, I'll go over some system-wide financial and operating metrics that offer added perspective on how we're doing overall and on the reach of our enterprise. We rely on these metrics to run the business, since they capture activity at every center we operate, whether wholly owned or operated through our joint ventures with health systems. Let's start with volume performance in Q3. We posted healthy growth throughout the enterprise, with sustained momentum in advanced modalities across the company, continued maturation of our de novo cohorts, and strong results from our health system partnerships. Advanced modality volumes, which typically reimburse at rates three to four times higher than routine modalities, stood out, rising 8.1% system-wide versus the prior year and 7.9% on a consolidated basis. As Caitlin mentioned, advanced modalities made up a record 38.2% of our volumes system-wide this quarter, which is 145 basis points above the prior year period. It's encouraging that these procedures have kept growing steadily. When we include routine scans, which grew more slowly because of our focus on advanced volumes, total system-wide volume growth for Q3 came to 4% over the prior year period, marking our highest growth rate so far in 2026. Now to our third quarter financials. Consolidated revenues, which reflect our wholly owned outpatient sites along with our professional service segment, reached $272 million, up 5% from the same period last year. System-wide outpatient revenue growth, covering all sites we operate, rose 7.7% over a year ago, driven by strong growth in advanced modalities. System-wide revenue per scan in our outpatient segment was up 3% year-over-year. That metric gives useful insight into outpatient economics because it captures both technical scan revenue and, where applicable, the related professional revenue. Our expanding advanced modalities contribute to this metric, along with modest increases in contracted payer rates, partly offset by payer mix shifts in a few markets. Here's a bit more detail on consolidated revenues in Q3. Outpatient net patient service revenues came to $149 million, growing 5.5% year-over-year on healthy same-site growth. Professional fee net patient service revenues were $62.1 million, up 2.6% year-over-year, in line with our model. And management fee and other revenues rose $3.6 million year-over-year, totaling $60.9 million. Within that management fee line, about $26 million comes from management fees we earn operating the sites in our health system JVs, which is our core business. The other $35 million in this category consists of zero margin pass-throughs of employee, IT, and site-level costs that we pay on behalf of a few of these joint venture sites. When you're modeling us, it matters that you understand those two components in terms of their impact on margin. Looking at expenses, G&A came in at $30 million for the quarter, which is $12.9 million above the third quarter of 2025. We had anticipated this, and it comes from $5.8 million in added costs split across two main items that have been affecting our year-over-year comparisons all through 2026. Let me walk through those. First, recurring costs tied to operating as a public company came in at $1.8 million for the quarter, as we expected, and for the full year 2026 we still expect roughly $7 million in such costs; after that, they'll sit in the prior-year base and stop driving year-over-year comparisons. Second, similar to last quarter, stock-based compensation rose from $8.3 million in Q3 2025 to $12.3 million in Q3 2026. That reflects the one-time resetting of legacy equity comp plans tied to our IPO. For full year 2026, we expect stock-based comp of about $50 million. Roughly half of that is tied to historic M&A and will be fully amortized by the end of 2026. Consequently, we still anticipate ongoing stock-based compensation of approximately $20 million-$28 million for full year 2027. Moving further down the income statement, the next line is equity and earnings of unconsolidated affiliates, which represents our pro rata ownership share of net income from sites we operate with health system partners. At $22.8 million, that was $4.9 million above Q3 2025, driven by notable strength this quarter at the sites we run with health system partners. Below that, interest expense was $15.7 million in Q3. This new run rate is roughly $14 million below Q3 2025, reflecting our use of IPO proceeds to pay down debt last December; that paydown unlocked more than $50 million in annualized cash interest savings and gave us more flexibility to invest in growth. Our term loan repricing in June of this year cut our SOFR spread by another 50 basis points. Pre-tax income for Q3 was $11.8 million, versus a pre-tax loss of $0.2 million in Q3 2025. After a tax provision of $4.6 million for the quarter, net income was $7.2 million in Q3, compared with a net loss of $3.5 million in Q3 of 2025. GAAP EPS was $0.07 per share in Q3, and adjusted EPS was $0.26 per share. Now I'll turn to adjusted EBITDA, which reflects strong operating performance across our entire network, our wholly owned centers, as well as our pro rata share from centers operated through health system joint ventures. Adjusted EBITDA grew 11% sequentially, reaching $62.6 million in the quarter, compared with $59.1 million a year ago. Underlying performance benefited from healthy overall volumes and sustained growth in advanced modalities, while reported growth absorbed incremental public company costs and planned investments associated with ramping our de novo centers. In Q3 2026 our adjusted EBITDA margin came in at 23.0%, versus 22.8% in Q3 2025, and this marked the first quarter since we went public that our margin rose on a year-over-year basis, even with $1.8 million in added costs tied to being a public company. On a sequential basis, adjusted EBITDA margin rose 160 basis points between Q2 and Q3. Turning to cash flows: cash flows from operating activities totaled $34.8 million in Q3 2026. That figure is $23 million above Q3 2025, reflecting lower debt under our senior credit facility along with the interest payments tied to it, plus growth in our earnings; we have made solid headway in working through the one-time impacts that pressured free cash flow earlier in the year. Free cash flow, which we define as cash flows from operating activities less CapEx, came to $20.6 million for Q3, versus negative $1.8 million in Q3 2025, an improvement of $22.4 million that produced conversion of roughly 32.9% of adjusted EBITDA. Our free cash flow conversion has been improving throughout the year, and with three quarters now complete, it is evident that we can grow this metric while still investing in our strategic priorities, which include de novo center adds and select M&A in a highly fragmented market. As a result, we are confident that 2026 free cash flow conversion will exceed our prior full year expectations, and we now expect a conversion rate of free cash flow to adjusted EBITDA of at least 30%.

Tony Martin executive
#5

Let me share a few remarks about CapEx. The opportunity in our market remains at an early stage — it is big, fragmented, and very appealing, and capturing it is why we are putting capital deployment first. As we chase meaningful returns, we keep applying rigorous discipline, investing in de novos, bringing new and upgraded equipment and capabilities to existing sites, and pursuing targeted M&A. Capital spending totaled $14.2 million in Q3 2026, which meant yet another quarter of heavy investment activity. Over the long term, our planned spending is basically the same as what we shared with you before. That said, because operating cash flow has been strong, we've decided to put somewhat more into CapEx in the back half of 2026, which lets us seize the opportunity we see ahead while still beating our free cash flow targets. Turning to the balance sheet: our capital position remains solid, and we closed the quarter with $90 million in cash and cash equivalents, compared with $69.7 million when the quarter began. Net leverage as of September 30 was 3.5x, down from 5.6x the year before. We remain firmly dedicated to a strategic approach to our capital structure—investing in our market opportunity and bringing leverage down as the business grows. Now, to wrap up with our outlook. We're pleased with how Q3 turned out, and that includes movement on every one of our main growth efforts — among them the gain in free cash flow conversion I touched on earlier, which keeps us on pace to reach free cash flow equal to at least 30% of adjusted EBITDA for the full year. With Q3 now completed, we are once more tightening the range for our adjusted EBITDA guidance, this time to $236 million-$240 million, compared with the prior range of $235 million-$241 million, and the midpoint stays at $238 million. That tighter range mirrors our results so far this year, how we see the business at present, and our ongoing confidence in the assumptions underpinning our guidance. When we talk about adjusted EBITDA, we're looking at the whole system-wide footprint—including our pro-rata share of joint venture results. Consolidated revenue guidance, on the other hand, only covers the centers we majority-own. That difference in scope, not any change in how we view either business, is why adjusted EBITDA guidance is moving lower in range while consolidated revenue guidance remains the same. Tonight we're reaffirming consolidated revenue guidance of $1.045 billion to $1.097 billion. We're also raising our adjusted EPS outlook to $0.86 to $0.90 per share, up from the previous range of $0.71 to $0.77 per share. The primary reason for that increase is a lower assumed effective tax rate for the year, and our underlying operating assumptions haven't changed. We're motivated by what lies ahead and by how far we've come this year, and we remain focused on carrying out our plans and closing out the year on a high note. With that said, let's move on to questions from your side. Operator, could you please open the line for questions?

Brian Tanquilut analyst
#6

Hi there, good afternoon, and I appreciate you taking my question. Caitlin, perhaps I'll begin with you. Advanced modalities appear to be expanding at a solid pace. You're mentioning increasing or leaning further into CapEx. If you could just tell us — I'd assume much of that is headed toward adding capacity there — but if you can give more detail on where CapEx is rising, how fast that turns into volume growth, and then your perspective on demand dynamics in advanced. Thanks.

Caitlin Zulla executive
#7

Yes. Thanks very much, Brian. I appreciate the question. So, we're extremely proud of our advanced modalities. During Q3, our system-wide advanced modalities rose 8.1%. As we noted in the script, our 38.2% of total volume marks a record high for the company, 145 basis points above a year ago, and then 80 basis points above what we had in Q2. We're accomplishing that through ongoing deliberate investment in our machines. We've discussed investing in FastScan, both through bolt-on subscriptions and machine upgrades. We're also putting money into upgrading our PET machines as we keep working through both absolute machine number growth and the capacity of our existing machines. We're excited to announce our three de novos that we opened in early November, and we reiterate that we feel good about the eight to 10 for the remainder of the year. A significant amount of growth CapEx is going toward opening our de novos in 2026, and also planning as we plan into 2027 for de novo openings; on the demand side, we continue to feel really strong in the markets where we operate, grateful for the strong partnership of our joint venture partners, as well as the opportunities ahead of us. Patient demand keeps increasing for advanced scheduling, advanced procedures, and we look forward to continuing to meet that at our existing and our de novo sites.

Brian Tanquilut analyst
#8

Great. Tony, my follow-up will be really quick. I noticed unit counts declined from one quarter to the next, on both the JV side and the consolidated side. I realize you added 3 units in November, but I am just wondering what is going on there regarding closures over the quarter. Thanks.

Tony Martin executive
#9

Of course. Are you talking about absolute site numbers specifically?

Brian Tanquilut analyst
#10

That's correct, yes.

Tony Martin executive
#11

Right. So the center count did decline; every so often we consolidate centers; we discuss what makes a strong market and having the density to support, obviously, staffing, connecting with the local referrer population, and then just the broader capacity to serve that market. Yes, we keep a rigorous approach to center management and long-term expansion. Yes, we closed a couple, and then you'll see additions as we reach the eight to 10 de novos for the full year.

Matthew Gillmor analyst
#12

Hi, thanks for asking. I'd like to ask about how EBITDA moves from the third quarter into the fourth quarter. Could you walk through some of the drivers? It looks like fairly normal seasonality, but I'm curious whether there are any factors worth flagging as we think about that progression.

Tony Martin executive
#13

Absolutely. As we've mentioned previously, we see the year unfolding with 45% of our EBITDA generated in the first half and 55% in the second half. The Q3 results are consistent with that sequencing. EBITDA grew 11% from Q2 to Q3, and we consider that an important proof point for what we discussed earlier in the year regarding how this business is shaped when it comes to in-year phasing. As Q4 approaches, we expect that trend to carry on and to close out the year consistent with that split we described.

Matthew Gillmor analyst
#14

That's great. So just quickly as a follow-up, Tony Martin, on free cash flow conversion — obviously it's great to see that move higher. Could you talk about some of the drivers behind your decision to raise the guide there?

Tony Martin executive
#15

Sure. Things are going nicely and we're turning cash at a strong rate, which is great. Everything rests on that. Still, we're genuinely happy to point toward a bigger figure and to carry momentum toward even better conversion rates later on, since we're able to do so while continuing to put money into growth. To address why this is an improvement over what we talked about in the spring: the things we expected to put the most pressure on cash flows at the start of the year actually came in better than we had anticipated. We mentioned a few of them at the time — specifically the timing of the JV distribution, which has not worked against us. Taxes are coming in better than our view at the beginning of the year, and working capital swings have been less severe than we expected back in the spring. What all of that does is simply let the business show through more clearly than we had thought. As we've mentioned on earlier calls, free cash flow is currently trending higher on a year-over-year basis, and we're glad to have that progress underway already in 2026.

Andrew Cooper analyst
#16

Hi everyone, and thanks for making the time. Perhaps to start, it seems like profitability at the JV, or the affiliated centers, was a pretty nice source of upside, at least relative to where we had been. I'd just love any call-outs you can offer on where you're seeing success there, anything operationally that stood out this quarter, and what that signals for Q1 and beyond as well.

Tony Martin executive
#17

Absolutely; we generally focus on system-wide when we talk, since the entire business is what we operate, but we do enjoy discussing what the health system joint venture structure delivers for us, because it is very strong and very durable. In this quarter, both segments of the business did very well. Growth in advanced modalities looked very similar across our joint ventures and consolidated. But on your point about JVs specifically, yes, I mean, we posted 8.1% system-wide advanced growth, which is pulled up somewhat by the JVs running higher than that. We also saw JV per scan revenue rise more than 3% for the quarter. Those two factors together drive a lot of the strength in how the JV performed, and the earnings were. As we've discussed previously, these joint ventures are really built to optimize demand, the rising demand for advanced modality scans. They were designed with that in mind regarding which modalities went into the sites, at a somewhat higher proportion than some of our other centers; we get solid contracting support there with health systems. We think they will always perform at the top end of our portfolio. That said, as we've noted, it can ebb and flow somewhat in any individual quarter.

Clarke Murphy analyst
#18

Hi there. Good evening, all, and I appreciate the question. I'd like to begin with labor. You've put several programs in place for recruiting and retention. Could you take us through a few of the benefits you're getting from those, plus give us a broader update on the labor environment and what you're observing out there?

Tony Martin executive
#19

To begin with, our labor costs remain manageable. They aren't delaying us or doing financial harm. I can attach a figure to that, and I believe Caitlin can explain part of the reason, since we are quite deliberate in how we handle this area of our business. I'd simply refer to figures from our P&L. Look at the year-over-year movement in equity comp flowing through our business, and that gets you to the true day-to-day cost. We keep seeing operating expenses rise roughly 5% per year, which is exactly where it has been. Keeping a healthcare workforce staffed is never simple, yet we're quite comfortable with our position on the numbers and with how our business can prosper alongside that. Caitlin, you have additional thoughts to-

Caitlin Zulla executive
#20

Right, absolutely. On the strategy front, we touched earlier on how much leverage comes from having density in our markets, and that definitely gives us room to maneuver when we're figuring out how to give our staff schedules that fit their lives and their families. We keep putting money into our radiologic technicians. We've talked up the Technologist Advancement Academy in the past, and Virtual MRI is still going live at more of our sites, adding redundancy and career pathing that helps facility operations. When it comes to radiologists, recruiting into Connexia is still going well for us. We're genuinely thrilled that Dr. Pirozz is coming aboard. What makes him such a great match is that he genuinely understands where AI can slot in and actually help during a radiologist's day, since he practices neuroradiology himself. He'll be reading for Connexia for us too, and he's shown he can take frontier models and turn them into tools that get built fast and then deliver cost-effective answers for radiologists, things like draft reporting and dictation support, that kind of thing. So we'll keep working to make it a place where strong, amazing clinicians want to come and work.

Benjamin Rossi analyst
#21

Hi there. Good afternoon, and thanks for taking my question. I'd like to build on what you said about your addressable market growing under site neutral. Would this rule change mostly raise the count of JV opportunities, or do you believe it also alters how partnerships are structured, perhaps by driving more health system referrals? I'm just curious whether you could walk through the main assumptions and the timeline involved in this change. Thanks.

Caitlin Zulla executive
#22

Yes. Thank you very much, Ben. We're really excited that this got finalized in the rule. Of course, it applies to off-campus HOPDs and non-contract-only scans. For context, at Lumexa roughly 12% of our scans are with contract, so most of what happens in the outpatient setting is without contract; we've had a lot of exciting conversations with outstanding JV partners, and those talks sit at various stages. The statute's finalization is quite recent, obviously, but we do see it as a chance to consider how we help health systems with their imaging strategy overall, and how they preserve patient access at a time when building high-cost beds keeps getting harder within a revenue-constrained reimbursement framework. So our model, when we speak with them, helps them widen access, keep patients inside their network, and clearly take part economically without depending on that hospital outpatient reimbursement premium. I believe it will definitely be a bit of both, Ben. It will involve how we serve patients through differentiated service mechanisms, and also whether some hospital outpatient departments ought to potentially be recredentialed as an IDTF so they better fit the reimbursement landscape. On that note, I want to pause and say how thrilled we are to be working with Advocate. That conversation certainly took place before site neutrality was finalized, but what excites us so much is that we're moving into a new state, Illinois, alongside a partner that already understands how we operate. We established a relationship with Atrium Health, which is part of Advocate, through our Carolinas Imaging Services in the Charlotte region, and now we get to build further on that together. What stands out about Advocate is certainly their scale. They have 70 hospital campuses. They serve roughly 5.5 million patients. When we think about Illinois, we're coming into a new market with a partner holding deep roots across Chicagoland, an extensive network of hospitals and referring physicians, and that gives us a truly exciting and solid starting point for expanding access to outpatient imaging, and importantly, for keeping patients connected to the care teams they know. And then, of course, when we think about Advocate, broader opportunities exist. They serve additional states in the Midwest and Southeast, but our focus is really on executing well in Illinois, and doing that gives us a strong foundation for exploring other markets together.

Stephen Baxter analyst
#23

Hi there, and thanks. I realize it's still a bit early, but since 2026 is coming in strongly, I'd love to hear any color on how you're viewing 2027 at this point. Based on what you know today, do you think we should perhaps be looking at a year that's more consistent from both an EBITDA and a revenue growth standpoint, maybe closer to your long-term expectations, and are there any known headwinds or tailwinds to keep in mind beyond what the prepared remarks covered regarding Medicare reimbursement? Thank you.

Tony Martin executive
#24

Sure, Stephen. First, I'll say the probably obvious thing, which is that we'll provide formal guidance in March, and anything I mention here is really just about the directionality of the business and some factors shaping our thinking at the moment. I'd say the number one thing we discussed early in the year was that this year would carry the kind of headwinds from the added PubCo costs, the investments we had to make to build departments performing functions that a public company requires. We brought that up earlier this year as something that would affect our growth rate versus 2025; we're tracking in line with expectations on that, but it did kind of move us away from the growth algorithm, and we get back to those ends. Once we're past that, the way we see it is that the long-term growth algorithm we talked about remains firmly in place; we view what's happened this year as validating what our plan said and what our strategy is. We're just glad that each quarter we can put up some proof points about that, and accordingly, focus on numbers that will be consistent with how we model the business long term, which was something like a 7% adjusted EBITDA with upward mobility from that as we deploy capital to grow through the de novos and some selected M&A. Kind of a long answer without getting specific, but I hope that helps in terms of how we think about it.

Caitlin Zulla executive
#25

So Stephen, I can offer a bit more detail regarding the Medicare Physician Fee Schedule. For Medicare, the preliminary read is slightly negative. Figure roughly negative 1%, and that figure accounts for JV and our profit-sharing arrangements, plus the favorable effect from the MIPS bonus payment outcomes. Turning to the commercial payer mix, as we mentioned, it is healthy and diverse. Negotiations are done for almost all of our 2027 rates. All told, we anticipate the final rule will have a limited effect on our reimbursement overall for 2027. As most people likely are aware, the impact comes in a little worse than the July proposed rule, largely because of a lower conversion factor; that stems from the lapsing of the temporary 2.5% increase that Congress put in place for 2026. Just as it has in several prior years, Congress could act before the year is out to partially or perhaps even fully undo the reduction and offer some form of legislative relief that might soften part of that 1% impact or the conversion factor decrease. Of course, we will plan around this, and we can definitely keep you updated on whether any impact arises.

Thomas Walsh analyst
#26

Hello, Thomas Walsh here, filling in for Andrew. Could you tell us what same-center systemwide revenue per scan growth was during the quarter, and also give your thoughts on pricing, the commercial payer mix, and collections compared with what you had expected?

Tony Martin executive
#27

Right. My apologies — could you repeat the second part of your question?

Caitlin Zulla executive
#28

Payer mix?

Thomas Walsh analyst
#29

Just-

Tony Martin executive
#30

Payer mix

Thomas Walsh analyst
#31

Taking a wider view, how are pricing, commercial payer mix and collections tracking against what you expected?

Tony Martin executive
#32

Yeah. Okay. Yes. I would say that from the standpoint of our trends and year over year, payer mix is basically a non-event. For several quarters now, we've been right where we are. There are just very small swings here and there. So there isn't much to report on that front; we do still have a really strong commercial book, and our rate per unit increases have come in consistent with, or in some cases even slightly better than, what we modeled this quarter. So that trend line is strong, and on the consolidated business we're up about 2.1% per unit, and for the JV businesses we're up over 3%. So that's a place where we're comfortable living and we think it's sustainable.

Matthew Mardula analyst
#33

Hello there. Matthew Mardula here, sitting in for Ryan Daniels. Thanks very much for taking all of our questions. About what you mentioned during the prepared remarks concerning the AI enablement tools for reporting and summarization that help boost radiologists' efficiency and cut down on that administrative burden, how much extra capacity or efficiency do you think you can keep unlocking as we move ahead with these AI tools, particularly into 2027? And on the bigger picture, what inning would you say you're in when it comes to incremental capacity or simply capturing operational efficiencies for radiologists through these AI tools going forward?

Caitlin Zulla executive
#34

Sure. Thanks very much, Matt. Yes, when we think about AI, we describe it across four categories. First, how do we improve our core operations, bringing in additional patients and serving more of them on the same machine? Second, how do we generate backend operational efficiencies via areas such as our revenue cycle and our call center? Third, how do we grow our strategic service lines, such as our breast arterial calcification? And then, naturally, how do we keep supporting our radiologists in their overall productivity? We're in the early days of working out how to support our radiologists specifically, and when we think about Dr. Piroz joining the organization, there have been enormous advancements even over the past 18 months in frontier models and their capacity to affect radiologists' efficiency and effectiveness. I'm really excited to watch Dr. Piroz take this to the next level. Obviously, he'll be focused on serving our internal operations. He'll focus on making the best use of AI technology to improve the patient and provider experience. Really, when I think about the ultimate goal, I want radiologists who feel like they can do their best work, deliver the highest quality care, and serve our patients. At the end of the day, I want to be sure we manage a reasonable radiologist turnaround time on the reports; that's our ultimate goal. Then I think about how we keep earning and growing our business. It will come from providing amazing results, high-quality subspecialist-read reports to our referring physicians faster than the market, and supporting our radiologists with that technology is key to making that vision real.

Caitlin Zulla executive
#35

Much appreciated. To wrap up, I'd like to express gratitude to the members of our team, our technologists, and our radiologists, since their dedication to our mission and to the patients and communities we serve continues to be the bedrock of all that we do. Thanks to everyone for the questions today. We carry strong momentum, an expanding network of health system partners, and deep confidence in our strategy, in how strong our team is, and in the opportunity ahead of us. We're eager to keep you informed about our progress going forward. Have a good evening.

Operator operator
#36

Thanks, everyone, for joining the call today. That wraps up the program. You’re welcome to disconnect now. Have a good day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Lumexa Imaging Holdings, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Lumexa Imaging Holdings, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.